Joint pain? You may have more options than you’ve been told.

Cartilage does not behave like most other tissues.

Unlike muscle, skin, or bone, cartilage has no direct blood supply. It depends on the joint environment for nutrition and support. It also lives under very specific biological and mechanical conditions. It needs the right loading, but it also needs the right recovery. Too little loading is not good. Too much loading is not good either.

That is one reason cartilage problems are often misunderstood. People assume it behaves like a muscle strain or a soft-tissue injury that will simply improve if you do more exercises. Cartilage is different. It responds to biology, mechanics, the joint environment, and time.

Cartilage can become damaged through trauma, overload, instability, poor alignment, previous injury, inflammatory disease, or infection.

A football injury, a fall, a twist, a dislocation, or a direct impact can create very high force through the cartilage surface. Sometimes the damage is sudden and obvious. Sometimes it begins with a smaller injury that is not fully recognised at the time, and the problem develops gradually because the joint continues to load abnormally.

That is why so-called wear and tear is often not that simple. In many cases, there is a reason why the joint has reached that point.

People often use the phrase wear and tear to describe osteoarthritis, but the reality is usually more complex.

Cartilage does not simply vanish for no reason. There are often contributing factors such as poor alignment, instability, previous injury, repeated overload, abnormal biomechanics, or an unhealthy joint environment. Inflammatory arthritis and infection can also damage cartilage.

So when people say wear and tear, what they are often describing is cartilage that has been exposed to the wrong forces, the wrong environment, or the wrong timing for too long.

No. That is a common myth.

Physiotherapy can be very helpful, but more is not always better, and exercise alone does not magically reverse cartilage damage. If exercise alone could fix established cartilage loss, we would never have needed cartilage surgery or joint replacement in the first place.

The issue is not that patients are lazy. The issue is that cartilage injury is not just a conditioning problem. It is a structural and biological problem as well.

Physiotherapy matters, but it has to be the right physiotherapy, at the right stage, for the right reason.

Cartilage damage can range from a small area of softening or fraying to full-thickness loss where the surface has worn right down to bone.

In early stages, the cartilage may soften, swell, or begin to fray. As the damage progresses, it can crack, flap, or thin out. In more advanced disease, the joint may become bone on bone.

That range matters, because not every cartilage problem belongs in the same treatment category.

ChondroFiller is a collagen-based treatment used as part of a cartilage regeneration strategy.

Traditionally, treatments of this type were associated more with keyhole surgery, but I have also used ChondroFiller in injection-based form in selected cases. The principle is to provide structural support and biological supplementation to the damaged cartilage environment.

It is not just about symptom relief. It is about supporting the environment in which cartilage healing may occur.

We now have a database of over 100 patients treated in this way, and the early results are very promising. In selected cases, it appears to support meaningful improvement, and in some patients it seems to be associated with regeneration of part of the cartilage surface.

Traditionally it sat more clearly in the surgical space, especially in arthroscopic use. When used in injection-based form, the discussion is different.

It is still a serious treatment and should not be approached casually, but in experienced hands it appears safe in selected patients and has shown encouraging results. Because it is collagen-based, one of its advantages is that it can provide substantial supplementation to the cartilage environment as part of a regenerative strategy.

The key point is that it has to be used thoughtfully, in the right joint, at the right stage, and for the right reason.

These treatments are better thought of as environmental support.

They are not there to act as structural scaffolds in the way ChondroFiller can. Their role is more about supporting the joint environment, lubrication, and the biological setting around the cartilage. In the right patient, that can be useful as part of a preservation, relief, or regeneration strategy.

Arthrosamid is different again.

It is not regenerative. It sits more in the relief and symptom-control category. Its role is to help improve how the joint environment behaves in osteoarthritis, especially in selected patients where symptom control and functional improvement are important goals.

I have performed over 1,000 Arthrosamid procedures in the last five years, so my view comes from substantial clinical experience. It can be very useful in the right patient, but it should not be oversold as a regenerative solution.

A simple way to think about it is this.

ChondroFiller offers more structural support and sits closer to a regenerative strategy.

Chondroitin or environmental-support injections are more about improving the joint environment.

Arthrosamid is not regenerative. It sits more in the relief and symptom-control category.

So although they may all be discussed in patients with joint pain, they are not doing the same job.

Yes, they can.

But they should not just be combined because they sound impressive. They need to be staged properly, for the right indication and in the right order. Combination treatment only makes sense when there is a clear biological and clinical reason for it.

That is where experience matters. The treatment has to match the stage of the joint problem, not the popularity of the product.

PRP can be useful, but it should not be treated as a magic answer.

For established cartilage damage, PRP on its own is rarely the whole solution. It makes more sense when used in combination with other treatments and when the wider biology and mechanics of the joint are also being addressed.

The joint problem is usually bigger than one injection.

It depends on the treatment and the patient.

With Arthrosamid, some sponsored studies may suggest longer duration, even up to five years. In my own clinical experience and database, if it works, around two years is a more realistic guide for many patients.

That is why honest follow-up and real-world data matter. Patients need realistic expectations, not just idealised claims.